Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, for the month of September 2016. The filing date is September 12, 2016. The report incorporates by reference a press release announcing a research collaboration with Stanford University regarding the company's product candidate, YELIVA.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to disclose a material event and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the establishment of a research collaboration with Stanford University focused on YELIVA. No financial changes versus prior periods are reported in this document.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the Stanford University collaboration. The filing does not provide specific guidance, risk factors, contingencies, or details on unusual items beyond the scope of the incorporated press release.
Key Facts for Investor Verification
- Verify the specific terms and scope of the research collaboration with Stanford University for YELIVA.
- Confirm the potential impact of this collaboration on the development timeline for YELIVA.
- Review the full text of the incorporated press release for details not included in this summary.
- Note that this filing contains no financial data; refer to the most recent Form 20-F for financial status.